N-epsilon-2,4-二硝基苯基-L-赖氨酸盐酸盐 | 14455-27-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-epsilon-2,4-二硝基苯基-L-赖氨酸盐酸盐
• 英文名称: Nε-2,4-dinitrophenyl-L-lysine hydrochloride
• 英文别名: (S)-6-(2,4-dinitrophenyl)aminohexanoic acid hydrochloride；N⁶-(2,4-dinitro-phenyl)-L-lysine ; hydrochloride；N⁶-(2,4-Dinitro-phenyl)-L-lysin; Hydrochlorid；Nepsilon-(2,4-Dinitrophenyl)-L-lysine hydrochloride；(2S)-2-amino-6-(2,4-dinitroanilino)hexanoic acid;hydrochloride
• CAS: 14455-27-7
• 化学式: C₁₂H₁₆N₄O₆*ClH
• 分子量: 348.743
• InChiKey: VDVXDUOPLKVMMM-FVGYRXGTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  167
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  N-epsilon-2,4-二硝基苯基-L-赖氨酸盐酸盐 在 氯化亚砜 、 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 methyl (S)-2-[[[(3,5,6-trichloro-2-pyridyl)oxy]methylcarbonyl]amino]-6-(2,4-dinitrophenyl)aminohexanoate
  参考文献：
  名称：

  New Approach to Immunochemical Determinations for Triclopyr and 3,5,6-Trichloro-2-pyridinol by Using a Bifunctional Hapten, and Evaluation of Polyclonal Antiserum

  摘要：

  The present work describes the design and synthesis of the structurally unique hapten, "bifunctional hapten", to produce a group-specific polyclonal antiserum to triclopyr and 3,5,6-trichloro-2-pyridinol. A bifunctional hapten was designed and synthesized by conjugating commercially available N-epsilon-2,4dinitrophenyl (DNP)-(L)-lySine to triclopyr, and then coupling this to carrier proteins such as bovine serum albumin (BSA). The synthesized bifunctional hapten greatly raised the antiserum titer in comparison with that of the conventional hapten, triclopyr. Antiserum with a sufficiently high titer to provide the determinations of targeted compounds was obtained only 63 days after the primary immunization. The obtained antiserum showed the highest affinity to triclopyr (IC50 = 3.5 nM) and 3,5,6-trichloro-2-pyridinol (IC50 = 5.1 nM) in homologous ELISA. The cross-reactivities to various agrochemicals and some chlorinated phenolic compounds were determined. Significant cross-reactivity was found to the herbicide 2,45-T. The antiserum reacted to both triclopyr and its metabolite. Assay sensitivity was evaluated for effects of various assay conditions, including pH value and concentrations of organic solvents and detergents. Under optimized assay conditions, the quantitative working range of triclopyr ELISA was from 0.1 to 5.2 ng/mL with a limit of detection (LOD) of 0.037 ng/mL, and an IC50 of 0.72 ng/mL. On the other hand, the quantitative working range of 3,5,6-trichloro-2-pyridinol ELISA was from 0.13 to 6.0 ng/mL with a LOD of 0.052 ng/mL, and an IC50 of 0.95 ng/mL. Water samples fortified with triclopyr or its metabolite at 1, 5, and 10 ng/mL were directly analyzed without extraction and cleanup by the proposed ELISA. The mean recovery was 101.6%, and the mean coefficient of variation (CV) was 7.1% in the case of the triclopyr ELISA. In the case of the 3,5,6-trichloro-2-pyridinol ELISA, the mean recovery was 99.8%, and the mean CV was 9.5%. The proposed ELISA turned out to be a powerful tool for monitoring of residual triclopyr or 3,5,6-trichloro-2-pyridinol in water samples at trace level.

  DOI：

  10.1021/jf0114684

文献信息

• [EN] CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS<br/>[FR] SUPPORTS SOLIDES POUR LA LIBÉRATION CONTRÔLÉE DE MÉDICAMENTS
  申请人：PROLYNX LLC

  公开号：WO2011140392A1

  公开（公告）日：2011-11-10

  The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.

  这项发明涉及在医疗应用中有用的固体支持物，可提供药物的控制释放，如肽、核酸和小分子。这些药物通过一个通过受控β消除释放药物或前药的连接与固体支持物共价偶联。
• PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES
  申请人：Santi Daniel V.

  公开号：US20110263502A1

  公开（公告）日：2011-10-27

  The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.

  本发明提供了一种允许体内控制和延长药物释放的方法和组合物。这些化合物要么是具有可调节释放速率的前药，要么是药物与大分子结合物，其具有可调节的控制释放速率。
• US8680315B2
  申请人：——

  公开号：US8680315B2

  公开（公告）日：2014-03-25
• US9387254B2
  申请人：——

  公开号：US9387254B2

  公开（公告）日：2016-07-12
• [EN] PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES<br/>[FR] PROMÉDICAMENTS ET CONJUGUÉS MÉDICAMENT-MACROMOLÉCULE AYANT DES TAUX DE LIBÉRATION DE MÉDICAMENT CONTRÔLÉS
  申请人：PROLYNX LLC

  公开号：WO2009158668A1

  公开（公告）日：2009-12-30

  The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.